3-N-Fmoc-amino-3-(2-T-butoxyphenyl)propionic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 3-N-Fmoc-amino-3-(2-T-butoxyphenyl)propionic acid
• 英文别名: 3-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[2-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid
• 化学式: C₂₈H₂₉NO₅
• 分子量: 459.5
• InChiKey: YZUVTWQBAVEHKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Carboxamide derivatives as therapeutic agents
  申请人：——

  公开号：US20020193432A1

  公开（公告）日：2002-12-19

  This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, &bgr;-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

  这项发明提供了某些化合物、其制备方法、包括这些化合物的药物组合物以及它们在治疗人类或动物疾病中的用途。该发明的化合物可用作调节高级糖基化终产物受体（RAGE）与其配体之间相互作用的调节剂，这些配体包括高级糖基化终产物（AGEs）、S100/calgranulin/EN-RAGE、β-淀粉样蛋白和amphoterin，用于管理、治疗、控制或作为辅助治疗人类因RAGE引起的疾病。这些疾病或疾病状态包括急性和慢性炎症、糖尿病后期并发症的发展，如增加的血管通透性、肾病、动脉粥样硬化和视网膜病变，阿尔茨海默病的发展、勃起功能障碍以及肿瘤侵袭和转移。
• Carboxamide Derivatives as Therapeutic Agents
  申请人：Mjalli M.M. Adnan

  公开号：US20080119512A1

  公开（公告）日：2008-05-22

  This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

  这项发明提供了某些化合物、它们的制备方法、包含这些化合物的药物组合物以及它们在治疗人类或动物疾病中的应用。该发明的化合物可用作高级糖基化终产物（AGEs）、S100/calgranulin/EN-RAGE、β-淀粉样蛋白和amphoterin等配体与其受体——高级糖基化终产物受体（RAGE）之间相互作用的调节剂，并可用于管理、治疗、控制或作为辅助治疗人类因RAGE引起的疾病。这些疾病或疾病状态包括急性和慢性炎症、糖尿病晚期并发症的发展，如增加的血管通透性、肾病、动脉硬化和视网膜病变，阿尔茨海默病的发展、勃起功能障碍以及肿瘤侵袭和转移。
• Carboxamide Derivatives As Therapeutic Agents
  申请人：Mjalli Adnan M.M.

  公开号：US20100286197A1

  公开（公告）日：2010-11-11

  This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

  本发明提供了某些化合物、它们的制备方法、包括这些化合物的药物组合物，以及它们在治疗人类或动物疾病中的应用。该发明的化合物可用作高级糖基化终产物（AGEs）、S100/calgranulin/EN-RAGE、β-淀粉样蛋白和amphoterin等配体与其受体——高级糖基化终产物受体（RAGE）之间相互作用的调节剂，并用于治疗由RAGE引起的人类疾病的管理、治疗、控制或作为辅助治疗。这些疾病或疾病状态包括急性和慢性炎症、糖尿病晚期并发症的发展，如增加的血管通透性、肾病、动脉硬化和视网膜病变，阿尔茨海默病的发展、勃起功能障碍以及肿瘤侵袭和转移。
• US7423177B2
  申请人：——

  公开号：US7423177B2

  公开（公告）日：2008-09-09
• US7776919B2
  申请人：——

  公开号：US7776919B2

  公开（公告）日：2010-08-17